Exploring the cardiorenal benefits of MR antagonism in CKD and T2D

📌Finerenone - Novel , selective , non- steroidal MRA

#ESCCongress @lamcardio @BiykemB @MihaiTrofenciuc @pabeda1 @AndrewJSauer @MeralKayikcoglu @ErinMichos @DrMarthaGulati @DavidLBrownMD @JamalRanaMD
Finerenone has a favorable safety profile across a wide dose range in patients with CKD and T2DM receiving a RAS blocker
#ESCCongress

@CMichaelGibson @JamalRanaMD @DrMarthaGulati @AnastasiaSMihai @onco_cardiology @DavidLBrownMD @biljana_parapid @AndrewJSauer @ShelleyZieroth
Finerenone Reduces CV Outcomes in Patients With Early #CKD, #Diabetes: #FIGARO-DKD

🎯 The study, when coupled with #FIDELIO-DKD, now opens up #finerenone to DM patients with a wide range of CKD

#ESCCongress @escardio @ESC_Lavinia @ASNKidney @NephroPath @kidney_boy @Hragy

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Henry Han, MBBS, MD

Henry Han, MBBS, MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @HanCardiomd

30 Aug
Iron deficiency as a therapeutic target in heart failure - new evidence, new guidelines

New evidence from AFFIRM-AHF ‒ implications for clinical practice with ⬆️QoL
#ESCCongress @ESC_Journals @escardio @ShelleyZieroth @hvanspall @DrNasrien @SilCastelletti @DrMarthaGulati
New evidence from AFFIRM-AHF ‒ implications for clinical practice on cost effectiveness and QoL

#ESCCongress @ESC_Lavinia @escardio @ESCardioNews @ShelleyZieroth @JavedButler1 @rachkataria @AndreasGevaert @AndrewJSauer @pabeda1 @BSHeartFailure @FH_Verbrugge @DrRyanPDaly
Very insightful presentation by @JavedButler1 on New evidence from meta-analyses ‒ lessons to learn on the benefits of intravenous ferric carboxymaltose in HF

#ESCCongress @JavedButler1 @DrNasrien @MihaiTrofenciuc @pabeda1 @AndrewJSauer @NMHheartdoc @hvanspall @MajaCikes
Read 5 tweets
29 Aug
Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt? - Joint with (ISCP)

Prevention of thromboembolism in COVID-19
#ESCCongress @escardio @ESC_Lavinia @Steph_Achenbach @susannaprice @mmamas1973 @fhussain73 @DrJennHaythe md
Read 8 tweets
28 Aug
FIGARO -DKD

FIGARO-DKD Finds Finerenone Offers CV Benefits in Mild to Moderate Kidney Disease With T2D; Cuts HF Hospitalization 29% @escardio #ESCCongress @JJheart_doc @AnastasiaSMihai @ESC_Journals @ShelleyZieroth @mmamas1973 @hvanspall @JavedButler1 @DrNasrien @aayshacader
A statistically significant 13% lower risk among those treated with finerenone, a benefit that was driven by a reduction in HHF (HR 0.71; 95% CI 0.56-0.90)

@escardio #ESCCongress @ShelleyZieroth @hvanspall @mmamas1973 @AnastasiaSMihai @DrNasrien @lamcardio @JavedButler1
The combined patient-level analysis of FIGARO-DKD and FIDELITY-DKD included 13,171 patients with #T2DM of whom 40% had preserved kidney function as defined by the eGFR ≥ 60 mL/min/1.73 m2 but elevated UACR

@escardio #ESCCongress @ESC_Journals @lamcardio @FaiezZANNAD
Read 4 tweets
28 Aug
The drug ⬇️ the risk of ≥ 50% ⬇️ in eGFR or renal death in EMPEROR-Reduced (HR 0.51; 95% CI 0.33-0.79), but not in EMPEROR-Preserved (HR 0.95; 95% CI 0.73-1.24) #ESCCongress @ESC_Lavinia @escardio
Read 6 tweets
27 Aug
Hot Line - EMPEROR-Preserved / EMPEROR-Pooled

EMPEROR-Preserved, and the “Very Elegant” SGLT2 Inhibitors, to Highlight #ESCCongress @ESC_Lavinia @ESCardioNews @DrNasrien @lamcardio @BiykemB @JavedButler1 @CMichaelGibson @Sarah_Moharem @pabeda1 @HFA_President @mmamas1973 @Hragy ImageImageImageImage
EMPEROR-Preserved

📌First landmark trial to show unequivocal clinical benefits with a drug in pts with HFpEF #ESCCongress
@ESC_Lavinia @escardio @ESC_Journals @pabeda1 @MKIttlesonMD @mirvatalasnag @DrRyanPDaly @mvaduganathan @JavedButler1 @DrMarthaGulati @GreggWStone ImageImageImage
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(